Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04050215 · ClinicalTrials.gov registry record · Phase 2
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
A Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 937
- Enrollment target
- 1
- Study location
NCT04050215 is a Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 937 participants, above the 209-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (348% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04050215, a Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 937 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scan on treatment strategies for patients with prostate cancer. Diagnostic imaging procedures, such as 68GA-PSMA-11 PET/CT scan, may help doctors plan the best treatment for prostate cancer.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- OTHER Questionnaire Administration
- DRUG Gallium Ga 68-labeled PSMA-11
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 937 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04050215
The ClinicalTrials.gov registry entry for NCT04050215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 937 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 209-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (348% higher). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT04050215 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04050215 about?
NCT04050215 is a clinical study titled "68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer". This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scan on treatment strategies for patients with prostate cancer. Diagnostic imaging procedures, such as 68GA-PSMA-11 PET/CT scan, may help doctors plan the best treatment for prostate ca...
What is the current status of trial NCT04050215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 937 participants. The study started on 2018-04-02. Estimated completion is 2021-09-27.
What conditions does trial NCT04050215 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT04050215?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Questionnaire Administration (OTHER), Gallium Ga 68-labeled PSMA-11 (DRUG).
Who is sponsoring clinical trial NCT04050215?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04050215 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.